ALBANY, N.Y., Sept. 14, 2015 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) today announced two promotions within the company's senior
management team. George Svokos,
Senior Vice President and Chief Commercial Officer, has been
promoted to Chief Operating Officer, and Lori M. Henderson, Senior Vice President,
General Counsel and Secretary, has added the role of head of
Corporate Business Development. They will continue to report to
AMRI President and CEO William S.
Marth.
AMRI's three business unit heads will report to Mr. Svokos and
he will continue to lead the Active Pharmaceutical Ingredient
(API) Manufacturing business for the present time. Ms. Henderson
will continue to head up AMRI's legal, mergers and acquisitions and
corporate affairs activities for the company's locations worldwide,
which includes the United States,
Europe and Asia.
"Aligning our leadership as we grow and move forward with our
strategy to be the preeminent supplier of custom and complex
end-to-end services to the pharmaceutical industry will ensure
AMRI's success as a whole," says William S.
Marth, President and CEO, AMRI. "Both George and Lori have
made significant contributions to AMRI, each demonstrating a
leadership and vision, while helping navigate the complex M&A
environment as the company continues to expand organically and
inorganically."
George Svokos joined Albany
Molecular Research, Inc. in January
2014. After serving as Senior Vice President Sales and
General Manager-API, he assumed responsibility as Chief Commercial
Officer. Before AMRI, Mr. Svokos was with Teva Pharmaceuticals
Industries Ltd., most recently as Senior Vice President, U.S.
Technical Operations.
Lori M. Henderson joined AMRI in
February 2011, and is responsible for
leading all of AMRI's legal, mergers and acquisitions and corporate
affairs activities for the company's locations worldwide, including
the United States, Europe and Asia. Before joining AMRI, she served as
general counsel, corporate secretary and chief administrative
officer for Rand Worldwide, Inc.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Solutions (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug metabolism and
pharmacokinetics, as well as natural products. API supports the
chemical development and cGMP manufacture of complex API, including
potent, controlled substances, biologics, peptides, steroids,
hormones, cytotoxic compounds and sterile API. DPM supports
development through commercial scale production of complex
liquid-filled and lyophilized parenterals, sterile suspensions and
ophthalmic formulations. For more information about AMRI, please
visit our website at www.amriglobal.com or follow us on
Twitter (@amriglobal).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-promotes-two-company-executives-to-key-positions-300142028.html
SOURCE AMRI